SynthesisClinical research in cardiology : official journal of the German Cardiac Society2014
Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.The Cochrane database of systematic reviews · 2020Pooled it
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.The Cochrane database of systematic reviews · 2018Pooled it
- Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.ESC heart failure · 2017Pooled it
- Investigating the role of acute mental stress on endothelial dysfunction: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Pooled it
- Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.ESC heart failure · 2018Trial
- A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Trial
- Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.Cardiovascular journal of AfricaTrial
- Levosimendan in the modern treatment of patients with acute heart failure of various aetiologies.Archives of medical science : AMS · 2021Article
- Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.Journal of cardiovascular pharmacology · 2020Review
- Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.Cardiac failure review · 2020Review
- Hemodynamic effects of inotropic drugs in heart failure: A network meta-analysis of clinical trials.Medicine · 2019Article
- Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.Journal of cardiovascular pharmacology · 2018Review
- The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2017Article
- The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2017Article
- Long-term intravenous inotropes in low-output terminal heart failure?Clinical research in cardiology : official journal of the German Cardiac Society · 2016Review
- Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death.Biochimica et biophysica acta · 2016Review
- Authors' reply concerning the letter by Ensminger et al.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsStandard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. METHODS AND
resultsFour investigators independently searched in CENTRAL, Google Scholar MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials to identify any randomized study ever performed with intermittent levosimendan intravenous administration in adult patients with chronic heart failure with no restrictions on dose or time of administration. Data from a total of 326 patients from six randomized controlled studies using intermittent levosimendan in a cardiological setting were included in the analysis. Levosimendan was associated with a significant reduction in mortality at the longest follow-up available [32 of 168 (19 %) in the levosimendan group 46 of 133 (35 %) in the control arm, RR = 0.55 (95 % CI 0.37-0.84), p for effect = 0 0.005, p for heterogeneity = 0.3, I (2) = 23.4 %, NNT = 6 with 5 studies included]. Brain natriuretic peptide values, ejection fraction and number of patients with New York Heart Association ≥ III status were similar in survivors of both groups.
conclusionsA large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.